

Master Collaboration Agreement with Illumina

RNS Number : 7706S

Novacyt S.A.

01 September 2026

NOVACYT

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Master Collaboration Agreement with Illumina

Agreement supports evaluation of future collaboration and product development opportunities

Paris, France, and Manchester, UK - 1 September 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has entered into a Master Collaboration Agreement ("MCA" or "Agreement") with Illumina (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, for an initial five-year term.

The Agreement establishes a framework under which the parties may explore potential future collaboration in areas of mutual interest, subject to separate written project agreements. Novacyt will provide expertise complementary to Illumina, to allow exploration of deeper product development and commercial collaboration. Novacyt looks forward to providing updates on any material developments arising from the relationship as appropriate.

Lyn Rees, Chief Executive Officer, said: *"The MCA establishes a strategic framework to facilitate knowledge sharing and training between Novacyt and Illumina and the potential to explore future collaboration, reflecting the value of Novacyt's product development capabilities."*

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Contacts

Novacyt SA	https://novacyt.com/investors
Lyn Rees, Chief Executive Officer	Via Walbrook PR
Steve Gibson, Chief Financial Officer	
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)	+44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)	
Singer Capital Markets (Joint Broker)	+44 (0) 20 7496 3000
Russell Cook / Graham Hertrich / James Fischer	
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit	+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings / William Turner	+44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7407 804 654 / +44 (0)7407 020 470



PRIMER
DESIGN

Yourgene
Health

SCD
SOUTHERN CROSS
DIAGNOSTICS

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical	Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation	Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology · genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
Research Use Only	Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region.

The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information

about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRDBGDIXDXDGLB